Skip to main content
. Author manuscript; available in PMC: 2018 May 5.
Published in final edited form as: Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9

Figure 7. Therapeutic evolution and survival outcome of metastatic ccRCC through the four different eras.

Figure 7

a | Prior to 2004, two drugs were available to treat RCC (with a median survival of ~15 months). This so-called dark age of treatments was followed by the modern age (2005–2014), which saw seven additional regimens gain approval (increasing median survival to ~30 months). Currently, the golden age has already witnessed the introduction of three drugs, with more anticipated over the next decade. b | These advances promise to be translated to a significant number of patients (~50%) achieving durable remissions under active surveillance by 2025 with a median survival of ~5 years. The ultimate goal is the future diamond age of drug approvals is >80% of patients with metastatic ccRCC long-term survival. Dashed lines represent predicted survival.